Major analysts like Citi, Needham, and Bank of America maintain Sell ratings on Sarepta after recent updates, citing risks to key products like Elevidys, lower 2026 outlook, and regulatory concerns in Duchenne muscular dystrophy treatments.
Sarepta Therapeutics reports positive three-year results for Elevidys gene therapy in Duchenne patients, showing 70% slowing of disease progression and sustained motor function improvements, boosting investor confidence.
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
Sarepta rises as HHS recommends newborn screening for Duchenne muscular dystrophy and metachromatic leukodystrophy, aiming for earlier diagnosis and treatment.
Dyne Therapeutics' experimental DMD treatment shows strong results in late-stage trial, potentially offering more effective alternative to current controversial therapies with 10x higher dystrophin levels.
Needham initiates Buy on Solid Biosciences with $16 target, highlighting potential of SGT-003 gene therapy amid concerns over Sarepta’s Elevidys safety.
